These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2032255)

  • 1. Immunoconjugates of Pseudomonas exotoxin A: evaluation in mice, monkeys, and man.
    Morgan AC; Manger R; Pearson JW; Longo D; Abrams P; Sivam G; Bjorn M
    Cancer Detect Prev; 1991; 15(2):137-43. PubMed ID: 2032255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice.
    Pearson JW; Sivam G; Manger R; Wiltrout RH; Morgan AC; Longo DL
    Cancer Res; 1989 Sep; 49(18):4990-5. PubMed ID: 2504482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.
    Pai LH; Batra JK; FitzGerald DJ; Willingham MC; Pastan I
    Cancer Res; 1992 Jun; 52(11):3189-93. PubMed ID: 1591729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon.
    Pearson JW; Hedrick E; Fogler WE; Bull RL; Ferris DK; Riggs CW; Wiltrout RH; Sivam G; Morgan AC; Groves E
    Cancer Res; 1990 Oct; 50(19):6379-88. PubMed ID: 2144790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
    Benhar I; Pastan I
    Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
    Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
    Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer.
    Pai LH; Bookman MA; Ozols RF; Young RC; Smith JW; Longo DL; Gould B; Frankel A; McClay EF; Howell S
    J Clin Oncol; 1991 Dec; 9(12):2095-103. PubMed ID: 1960550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma.
    Kreitman RJ; Puri RK; Pastan I
    Cancer Res; 1995 Aug; 55(15):3357-63. PubMed ID: 7614471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of human cervical carcinoma with monoclonal antibody-Pseudomonas exotoxin conjugates.
    Roffler SR; Yu MH; Chen BM; Tung E; Yeh MY
    Cancer Res; 1991 Aug; 51(15):4001-7. PubMed ID: 1855216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.
    Alderson RF; Kreitman RJ; Chen T; Yeung P; Herbst R; Fox JA; Pastan I
    Clin Cancer Res; 2009 Feb; 15(3):832-9. PubMed ID: 19188153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotoxins of Pseudomonas exotoxin A (PE): effect of linkage on conjugate yield, potency, selectivity and toxicity.
    Morgan AC; Sivam G; Beaumier P; McIntyre R; Bjorn M; Abrams PG
    Mol Immunol; 1990 Mar; 27(3):273-82. PubMed ID: 2342490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity.
    Theuer CP; Kreitman RJ; FitzGerald DJ; Pastan I
    Cancer Res; 1993 Jan; 53(2):340-7. PubMed ID: 8417828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent.
    Debinski W; Pastan I
    Cancer Res; 1992 Oct; 52(19):5379-85. PubMed ID: 1394141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotoxin therapy for cancer.
    Pai LH; Pastan I
    JAMA; 1993 Jan; 269(1):78-81. PubMed ID: 8416411
    [No Abstract]   [Full Text] [Related]  

  • 15. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.
    Onda M; Nagata S; Tsutsumi Y; Vincent JJ; Wang Q; Kreitman RJ; Lee B; Pastan I
    Cancer Res; 2001 Jul; 61(13):5070-7. PubMed ID: 11431343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
    Puri RK; Hoon DS; Leland P; Snoy P; Rand RW; Pastan I; Kreitman RJ
    Cancer Res; 1996 Dec; 56(24):5631-7. PubMed ID: 8971168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomonas exotoxin: recombinant conjugates as therapeutic agents.
    FitzGerald DJ; Pastan I
    Biochem Soc Trans; 1992 Nov; 20(4):731-4. PubMed ID: 1487051
    [No Abstract]   [Full Text] [Related]  

  • 18. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.
    Batra JK; Kasprzyk PG; Bird RE; Pastan I; King CR
    Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5867-71. PubMed ID: 1352878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomonas exotoxin--immunotoxins.
    FitzGerald DJ; Willingham MC; Pastan I
    Cancer Treat Res; 1988; 37():161-73. PubMed ID: 2908624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma.
    Onda M; Wang QC; Guo HF; Cheung NK; Pastan I
    Cancer Res; 2004 Feb; 64(4):1419-24. PubMed ID: 14973056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.